| HOME >> BIOLOGY >> TECHNOLOGY |
Newly enhanced Web site designed as an easy-to-navigate tool for consumers Web site developed with recommendations and feedback from an expert in the
field of ADHD
PHILADELPHIA, July 29 /PRNewswire-FirstCall/ -- Shire Limited (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced today the re-launch of its educational Web site, ADHDSupport.com, designed to provide families, caregivers, educators and patients with tools and resources about Attention Deficit Hyperactivity Disorder (ADHD). The newly enhanced ADHDSupport.com provides visitors with some information about the evaluation process and management of the disorder, as well as tools and practical tips to help patients with ADHD manage their daily activities.
"ADHD is a common psychiatric disorder that can impact the lives of many people, including patients, caregivers, friends and co-workers. It has certainly impacted my own life both personally and professionally," said Michele Novotni, Ph.D., internationally recognized ADHD expert, former president and CEO of the national Attention Deficit Disorder Association (ADDA), psychologist and consultant in the development of ADHDSupport.com. "Because I have seen the pain of unrealized dreams and untapped potential first-hand among those with ADHD, I am passionate about providing information about ADHD in easily accessible formats. In fact, there are many people who do not realize that they or their children may have ADHD and many are unaware of the resources available to help individuals with ADHD find out more about the disorder. After reviewing ADHDSupport.com from a clinical and personal perspective, I can confirm that the Web site is a helpful tool for support and information about ADHD."
The re-designed ADHDSupport.com provides visitors, especially those who
may be new to ADHD, with an easy-to-navigate road map to help learn about
ADHD and finding daily successes while living
'/>"/>
| SOURCE Shire Limited Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |